When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRK - Surface Oncology collaborates with Merck for immuno-oncology study; shares up 35%
Merck & Company Inc.
Surface Oncology (NASDAQ:SURF) is up 35% premarket after entering into a clinical trial collaboration with Merck (NYSE:MRK) to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the U.S.
More news on: Surface Oncology, Inc., Merck & Co., Inc., Healthcare stocks news, Stocks on the move,